Skip to main content
Article thumbnail
Location of Repository

Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents?

By Kamal Chitkara and Kushal Pujara


The published version is also freely available and accessible from the publisher's webiste. The European Journal of Cardiovascular Medicine is an Open Access journal.\ud This article is also freely available in PubMed.Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of\ud interventional cardiology by having a major impact on patient care through their efficacy in reducing\ud the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative\ud agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after\ud stenting, have been evaluated; four of these devices are currently approved by the U.S. Food and Drug Administration (FDA). Bare metal stent (BMS) and first-generation DES, such as sirolimus-\ud eluting (SES-Cypher®) and paclitaxel-eluting stents (PES-Taxus®), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of\ud restenosis. However, there is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis (LST), especially after discontinuation of dual antiplatelet therapy.\ud Second-generation DES, such as zotarolimus-eluting (ZES-Endeavor®) and everolimus-eluting stents (EES-Xience V®), are become available in the USA and/or Europe. Recently, long-term results\ud comparing DES with BMS in patients with ST-segment-elevation MI (STEMI) have raised some\ud questions about the long-term risks of the drug-eluting devices. It may be useful to pause, reflect for a moment, and consider some recent pertinent results regarding their wider use. This\ud systematic review tries to provide a concise and critical appraisal of the data available to compare\ud first and second generation stents especially to assess risk of stent thrombosis (ST) with second-\ud generation DES.Peer-reviewedPublisher PD

Topics: coronary disease, angioplasty, thrombosis, restenosis, stents
Publisher: Healthcare Bulletin
Year: 2010
DOI identifier: 10.5083/ejcm.20424884.10
OAI identifier:

Suggested articles


  1. (2004). 279: 169–197. Rensing
  2. (2009). A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet doi
  3. (2001). Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. doi
  4. (2004). de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. doi
  5. (2010). Efficacy and safety of zotarolimus-eluting and sirolimuseluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet doi
  6. ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. doi
  7. (2005). Evaluation of four-year coronary artery response after sirolimuseluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. doi
  8. (2007). PJ; ENDEAVOR I Investigators. Four-year clinical follow-up after implantation of the endeavor zotarolimuseluting stent: ENDEAVOR I, the first-in-human study. doi
  9. (2003). Randomized study to assess the effectiveness of slow- and moderaterelease polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. doi
  10. (2010). Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet doi
  11. (2003). Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial doi
  12. (2003). Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. doi
  13. (2009). SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxeleluting stents in patients with coronary artery disease. Am Heart J. doi
  14. (2001). Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. doi
  15. (2004). The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.